Literature DB >> 11356976

The adenovirus type 5 E1B-55K oncoprotein actively shuttles in virus-infected cells, whereas transport of E4orf6 is mediated by a CRM1-independent mechanism.

T Dosch1, F Horn, G Schneider, F Krätzer, T Dobner, J Hauber, R H Stauber.   

Abstract

The E1B-55K and E4orf6 proteins of adenovirus type 5 are involved in viral mRNA export. Here we demonstrate that adenovirus infection does not inhibit the function of the E1B-55K nuclear export signal and that E1B-55K also shuttles in infected cells. Even during virus infection, E1B-55K was exported by the leptomycin B-sensitive CRM1 pathway, whereas E4orf6 transport appeared to be mediated by an alternative mechanism. Our results strengthen the potential role of E1B-55K as the "driving force" for adenoviral late mRNA export.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11356976      PMCID： PMC114281          DOI： 10.1128/JVI.75.12.5677-5683.2001

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  31 in total

1.  Investigation of nucleo-cytoplasmic transport using UV-guided microinjection.

Authors:  R H Stauber; F Krätzer; G Schneider; N Hirschmann; J Hauber; O Rosorius
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

2.  Adenovirus late gene expression does not require a Rev-like nuclear RNA export pathway.

Authors:  C Rabino; A Aspegren; K Corbin-Lickfett; E Bridge
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Nuclear export signal located within theDNA-binding domain of the STAT1transcription factor.

Authors:  K M McBride; C McDonald; N C Reich
Journal:  EMBO J       Date:  2000-11-15       Impact factor: 11.598

4.  Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence.

Authors:  M Dobbelstein; J Roth; W T Kimberly; A J Levine; T Shenk
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

5.  The nuclear export signal within the E4orf6 protein of adenovirus type 5 supports virus replication and cytoplasmic accumulation of viral mRNA.

Authors:  S Weigel; M Dobbelstein
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells.

Authors:  P Sarnow; Y S Ho; J Williams; A J Levine
Journal:  Cell       Date:  1982-02       Impact factor: 41.582

7.  Two distinct activities contribute to the oncogenic potential of the adenovirus type 5 E4orf6 protein.

Authors:  M Nevels; S Rubenwolf; T Spruss; H Wolf; T Dobner
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

8.  Adenovirus early region 1B 58,000-dalton tumor antigen is physically associated with an early region 4 25,000-dalton protein in productively infected cells.

Authors:  P Sarnow; P Hearing; C W Anderson; D N Halbert; T Shenk; A J Levine
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

9.  Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein.

Authors:  N C Reich; P Sarnow; E Duprey; A J Levine
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

10.  Mouse-human heterokaryon analysis with a 33258 Hoechst-Giemsa technique.

Authors:  F G Moser; B P Dorman; F H Ruddle
Journal:  J Cell Biol       Date:  1975-09       Impact factor: 10.539
View more
  26 in total

1.  E4orf6 variants with separate abilities to augment adenovirus replication and direct nuclear localization of the E1B 55-kilodalton protein.

Authors:  Joseph S Orlando; David A Ornelles
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex.

Authors:  E Querido; P Blanchette; Q Yan; T Kamura; M Morrison; D Boivin; W G Kaelin; R C Conaway; J W Conaway; P E Branton
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

3.  Effects of mutations in the adenoviral E1B 55-kilodalton protein coding sequence on viral late mRNA metabolism.

Authors:  Ramon A Gonzalez; S J Flint
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  An activity associated with human chromosome 21 permits nuclear colocalization of the adenovirus E1B-55K and E4orf6 proteins and promotes viral late gene expression.

Authors:  Amy M Chastain-Moore; Terry Roberts; Deborah A Trott; Robert F Newbold; David A Ornelles
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

5.  CRM1-dependent transport supports cytoplasmic accumulation of adenoviral early transcripts.

Authors:  Melanie Schmid; Ramon A Gonzalez; Thomas Dobner
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

6.  Timely synthesis of the adenovirus type 5 E1B 55-kilodalton protein is required for efficient genome replication in normal human cells.

Authors:  Jasdave S Chahal; S J Flint
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

7.  The second open reading frame of the avian reovirus S1 gene encodes a transcription-dependent and CRM1-independent nucleocytoplasmic shuttling protein.

Authors:  Celina Costas; José Martínez-Costas; Gustavo Bodelón; Javier Benavente
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  Adenovirus ubiquitin-protein ligase stimulates viral late mRNA nuclear export.

Authors:  Jennifer L Woo; Arnold J Berk
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Adenovirus E1B 55-kilodalton protein is required for both regulation of mRNA export and efficient entry into the late phase of infection in normal human fibroblasts.

Authors:  Ramon Gonzalez; Wenying Huang; Renee Finnen; Courtney Bragg; S J Flint
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

10.  The respiratory syncytial virus matrix protein possesses a Crm1-mediated nuclear export mechanism.

Authors:  Reena Ghildyal; Adeline Ho; Manisha Dias; Lydia Soegiyono; Phillip G Bardin; Kim C Tran; Michael N Teng; David A Jans
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.